Article thumbnail

Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels

By Roberto Valle, Nadia Aspromonte, Loredano Milani, Frank W. Peacock, Alan S. Maisel, Massimo Santini and Claudio Ronco

Abstract

The study tests the hypothesis that in patients admitted with acutely decompensated heart failure (ADHF), achievement of adequate body hydration status with intensive medical therapy, modulated by combined bioelectrical vectorial impedance analysis (BIVA) and B-type natriuretic peptide (BNP) measurement, may contribute to optimize the timing of patient’s discharge and to improve clinical outcomes. Three hundred patients admitted for ADHF underwent serial BIVA and BNP measurement. Therapy was titrated to reach a BNP value of <250 pg/ml, whenever possible. Patients were categorized as early responders (rapid BNP fall below 250 pg/ml); late responders (slow BNP fall below 250 pg/ml, after aggressive therapy); and non-responders (BNP persistently >250 pg/ml). Worsening of renal function (WRF) was evaluated during hospitalization. Death and rehospitalization were monitored with a 6-month follow-up. BNP value on discharge of ≤250 pg/ml led to a 25% event rate within 6 months (Group A: 17.4%; Group B: 21%, Chi2; n.s.), whereas a value >250 pg/ml (Group C) was associated with a far higher percentage (37%). At discharge, body hydration was 73.8 ± 3.2% in the total population and 73.2 ± 2.1, 73.5 ± 2.8, 74.1 ± 3.6% in the three groups, respectively. WRF was observed in 22.3% of the total. WRF occurred in 22% in Group A, 32% in Group B, and 20% in Group C (P = n.s.). Our study confirms the hypothesis that combined BNP/BIVA sequential measurements help to achieve adequate fluid balance status in patients with ADHF and can be used to drive a “tailored therapy,” allowing clinicians to identify high-risk patients and possibly to reduce the incidence of complications secondary to fluid management strategies

Topics: Article
Publisher: Springer US
OAI identifier: oai:pubmedcentral.nih.gov:3151484
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2001). A
  2. (1994). A new method for monitoring body fluid variation by biompedance analysis: the RXc graph.
  3. (1994). Accuracy of bioelectrical impedance analysis in estimation of extracellular space in healthy subject and in fluid retention states.
  4. (2009). Acute heart failure syndromes.
  5. (2006). B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure.
  6. (2008). B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure.
  7. (1996). Bioelectrical impedance analysis in body composition measurement. In: Proceedings of a national institutes of health technology assessment conference.
  8. (2008). Cardiorenal syndrome.
  9. (2005). Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure.
  10. (2006). Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database.
  11. (2009). Clinical review: RIFLE and AKIN–time for reappraisal.
  12. (1991). Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care.
  13. (2010). Current techniques of fluid status assessment.
  14. (2010). Dei Cas L
  15. (2006). Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.
  16. (2008). Fluid balance as a biomarker: impact of fluid overload on outcome in critically ill patients with acute kidney injury. Critical Care 12:169–172 Heart Fail Rev
  17. (2005). How well does B-type-natriuretic peptide predict death and cardiac events in patients with heart failure: a systematic review.
  18. (2004). Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.
  19. (2009). Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease.
  20. (2009). Measuring impedance in congestive heart failure: current options and clinical applications.
  21. (2002). Patterns of bioelectrical impedance vector analysis: learning from electrocardiography and forgetting electric circuit models.
  22. (2007). Patterns of weight change preceding hospitalization for heart failure.
  23. (2001). Practical approaches to treating patients with acute decompensated heart failure.
  24. (1999). Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data.
  25. (2001). Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure.
  26. (2002). Rapid optimization: strategies for optimal care of decompensated congestive heart failure patients in the emergency department. Rev Cardiovasc Med 3:S41–S48
  27. (2004). Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes.
  28. (2002). Ryde ´n L
  29. (2008). Solal AC
  30. (2008). State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10:824–839 Heart Fail Rev
  31. (2007). Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations,
  32. (2006). The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients.
  33. (2004). The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9:195–201
  34. (2009). The cardiorenal syndrome.
  35. (1971). The natural history of CHF. The Framingham study.
  36. (2002). The prognostic importance of different definitions of worsening renal function in congestive heart failure.
  37. (2008). The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure.
  38. (2008). uidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure
  39. (2010). Use of brain natriuretic peptide and bioimpedance to guide therapy in heart failure patients.
  40. (2008). Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance.
  41. (2007). Young JB; OPTIMIZE-HF Investigators and hospitals characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.